On March 7, 2025, Advanced Biomed Inc. raised $6.56 million in its IPO and began trading on Nasdaq under the ticker “ADVB.” The biotech firm, which develops semiconductor-based microfluidic technology for early cancer detection, issued 1.64 million shares at $4 each, with an option to purchase an additional 246,000 shares within 45 days.
Current Share Price:
Established in 2014, Advanced Biomed has developed a proprietary microfluidic platform that functions as a compact laboratory on a chip. This system captures and enriches circulating tumor cells (CTCs) and related biomarkers from patient blood samples using a physical, antigen-independent method — offering an alternative to conventional antibody-based techniques.
Rather than targeting specific biomarkers that may be absent on some cancer cells, its diagnostic devices, including the A+Pre and AC-1000, employ semiconductor nano-biosensors and microfluidic chips to physically trap and analyze cells.
A+Pre reduces blood viscosity to ensure smooth processing, while AC-1000 separates and enriches CTCs and related tumor markers, working together to enhance the efficiency and accuracy of liquid biopsy testing.
Some research suggests that optimized microfluidic devices can isolate rare CTCs with recovery rates exceeding those of conventional methods — sometimes reaching over 90% under ideal conditions.
Recent pre-mass production trials — tests conducted to ensure that the devices meet performance and manufacturing quality standards before full-scale production —demonstrated that the A+Pre chip recovered 94% of tumor cells, while the AC-1000 achieved a 79.5% recovery rate, surpassing their performance targets.
These rigorous tests support the technology’s potential to deliver reliable, accurate results in clinical settings.
Advanced Biomed has also advanced commercialization efforts through collaborations with manufacturers Riva and Unimold, successfully trialing the production of its microfluidic chips.
Additionally, both the A+Pre and AC-1000 devices have secured clearance from China’s National Medical Products Administration (NMPA).
Looking ahead, the company plans to expand into North American and European markets by preparing localized production and regulatory filings, and it aims to initiate clinical research for its A+LCGuard lung cancer screening kit by mid-2025 — underscoring its commitment to rapid, affordable and reliable diagnostics.
In the broader cancer detection space, Grail, in partnership with Quest Diagnostics, recently rolled out its Galleri multi-cancer early detection (MCED) test, which screens for over 50 cancers through a simple blood draw by analyzing circulating tumor DNA (ctDNA). Grey’s Anatomy actress Kate Walsh has joined Grail’s Generation Possible initiative to raise awareness of MCED, drawing on her own family experience with cancer.
The global expansion of early detection technologies is further highlighted by a Dallas-based liquid biopsy test from Cancer Check Labs, capable of detecting up to 200 types of solid tumors by extracting intact CTCs — reinforcing the growing international demand for scalable diagnostic solutions.
In clinical practice news, Labcorp announced that its liquid biopsy test, Labcorp Plasma Complete, is now clinically available to guide oncologists toward treatment decisions for patients with advanced or metastatic cancers by analyzing ctDNA for genetic mutations across 521 genes.
Join or login to leave a comment
JOIN LOGIN